Sanofi-aventis
Healthcare Professional Web Site
For U.S. Residents Only

Glycemic Control with Apidra®

The Flexibility to be used in both type 1 and type 2
adult diabetes patients

Apidra® provides effective glycemic control
for type 2 diabetes patients

Comparable reductions in A1C vs RHI in type 2 diabetes patients (mean BMI=34.55)2,10

Mean change in A1C(%) from baseline* (N=876)2,10 Baseline change chart

A 26-week, randomized, open-label, active-control study compared Apidra® with RHI given premeal (both groups were given intermediate-acting basal insulin twice daily; mean baseline A1C <7.6%).² "Endpoint" was the last available measurement after start of treatment.¹ Apidra® or RHI was individually dosed as appropriate prior to at least 2 meals a day (breakfast and dinner).¹ The mean number of daily short-acting insulininjections at endpoint was 2.27 for Apidra® (n=404) and 2.24 for RHI (n=403).² The mean BMI was 34.55 kg/m².
*The baseline A1C value was 7.57% for Apidra® and 7.50% for RHI.²
  • Reductions from baseline were similar between both treatment groups2
  • The clinical relevance of the differences in A1C reduction between RHI and Apidra® is unknown
  • Efficacy was maintained regardless of presence or absence of oral hypoglycemic agent use10

Postprandial control achieved with both Apidra® and RHI in type 2 diabetes patients

  • Significantly lower mean blood glucose levels from baseline at 2 hours postbreakfast and 2 hours postdinner10
  • Apidra ® and RHI provided consistently low premeal blood glucose levels10

Apidra® provides effective glycemic control for type 1 diabetes patients

Equal reductions in A1C vs lispro in type 1 diabetes patients(mean BMI=24.99)1,2

IMPORTANT SAFETY INFORMATION FOR APIDRA®

Apidra® is a rapid-acting human insulin analog indicated to improve glycemic control in adults with type 2 diabetes or adults and children (4 years and older) with type 1 diabetes. Apidra® is contraindicated during episodes of hypoglycemia and in patients hypersensitive to Apidra® or any of its excipients. Apidra® should normally be used in regimens that include a longer-acting insulin.

OptiClik® is a reusable insulin delivery device for use with a 3-mL Apidra® cartridge (U-100). Needles, OptiClik® and cartridge systems must not be shared.

Apidra® has a more rapid onset and shorter duration of action than regular human insulin. When used as a mealtime insulin, the dose of Apidra® should be given within 15 minutes before or within 20 minutes after starting a meal. Glucose monitoring is essential for patients receiving insulin therapy. Any change in insulin and/or regimen should be made cautiously, only under medical supervision, and may require a change in dose. Concomitant oral antidiabetic treatment may need to be adjusted. As with all insulin preparations, the time course of Apidra® action may vary by individual or at different times in the same individual and depends on injection site, blood supply, temperature, and level of physical activity.

Hypoglycemia is the most common adverse reaction of insulin therapy, including Apidra®. The timing of hypoglycemia usually reflects the time-action profile of the administered insulin formulations. Other adverse events associated with Apidra® include hypokalemia, allergic reactions, injection site reactions, lipodystrophy, pruritus, and rash. Less common, but potentially more serious or life-threatening, is generalized allergy to insulin, including anaphylactic reactions.

Apidra® should not be mixed with other insulins or with a diluent when used in the pump.

Please click here for full prescribing information for Apidra®

sanofi aventis
Prescription Apidra® is available in pharmacies.


© 2002-2009 sanofi-aventis U.S. LLC. All rights reserved.
Legal Disclaimer Information and Privacy Policy
Questions or Comments? Click here to contact us.
This site intended for use by US residents only.
US.GLU.06.06.027 Last Update: July 2006
Flash Player
Flash Player

You need a Flash Player in order to view some content. You are about to be directed to Macromedia Flash Player Download Center.

Click the CONTINUE button below to go to the Macromedia Flash Player Download Center, or the CANCEL button to return to the previous page.

NOTE: After installation is complete, please restart your browser.

Cancel
Continue
Flash Player